[1]张凌捷,葛 睿,程爱群,等.乳腺癌患者血清NR3C2 和DNMT3A 表达水平及其诊断价值研究[J].现代检验医学杂志,2023,38(06):120-124.[doi:10.3969/j.issn.1671-7414.2023.06.022]
　ZHANG Lingjie,GE Rui,CHENG Aiqun,et al.Expression Levels of Serum NR3C2 and DNMT3A in Breast Cancer Patients and Their Diagnostic Value[J].Journal of Modern Laboratory Medicine,2023,38(06):120-124.[doi:10.3969/j.issn.1671-7414.2023.06.022]
点击复制

乳腺癌患者血清NR3C2 和DNMT3A 表达水平及其诊断价值研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第38卷
期数:
2023年06期
页码:
120-124
栏目:
论著
出版日期:
2023-11-15

文章信息/Info

Title:
Expression Levels of Serum NR3C2 and DNMT3A in Breast Cancer Patients and Their Diagnostic Value
文章编号:
1671-7414（2023）06-120-05
作者:
张凌捷; 葛 睿; 程爱群; 胡天华
（复旦大学附属华东医院普外科，上海 200040）
Author(s):
ZHANG Lingjie; GE Rui; CHENG Aiqun; HU Tianhua
（Department of General Surgery，Huadong Hospital Affiliated to Fudan University，Shanghai 200040，China）
关键词:
乳腺癌; 核受体亚家族C 组成员2; DNA 甲基化转移酶-3A
分类号:
R737.9；R730.43
DOI:
10.3969/j.issn.1671-7414.2023.06.022
文献标志码:
A
摘要:
目的 探讨乳腺癌患者血清核受体亚家族C 组成员2（nuclear receptor subfamily 3, group C, member 2，NR3C2），DNA 甲基化转移酶-3A[DNA(cytosine-5)-methyltransferase 3A，DNMT3A] 水平及其临床诊断价值。方法 收集复旦大学附属华东医院2017 年5 月～ 2020 年12 月期间住院的94 例乳腺癌患者为乳腺癌组，另选取同期健康体检者86 例作为对照组。酶联免疫吸附试验(enzyme-linked immunosorbent assay，ELISA）检测两组血清NR3C2 和DNMT3A水平，Pearson 法分析乳腺癌患者血清NR3C2 和DNMT3A 表达水平相关性，多因素Logistic 回归分析乳腺癌发生的影响因素，受试者工作特征（receiver operating characteristic，ROC）曲线评估NR3C2 和DNMT3A 对乳腺癌的诊断价值。结果 乳腺癌组患者血清NR3C2 水平为317.84±33.47 ng/L，低于对照组（374.25±47.72ng/L），DNMT3A的表达水平为451.63±75.47μg/L，高于对照组（349.85±63.72 μg/L），差异有统计学意义（t=9.243，9.729，均P<0.05）。Pearson 分析结果显示，乳腺癌患者血清NR3C2 与DNMT3A 表达水平存在明显负相关（r=-0.501，P=0.000）。Logistic 回归分析结果显示，NR3C2 高水平为乳腺癌发生的保护因素（OR=0.563，95%CI：0.372 ～ 0.851，P=0.006），DNMT3A 高水平是乳腺癌发生的危险因素（OR=1.834，95%CI：1.249 ～ 2.693，P=0.002）。ROC 曲线结果发现，血清NR3C2 与DNMT3A 诊断乳腺癌的曲线下面积（area under the curve，AUC）分别为0.853（0.791 ～ 0.915），0.930（0.896 ～ 0.965），当两者联合时其AUC 为0.969（0.949 ～ 0.990），高于两者单独检测（Z=3.460，1.894，P=0.000，0.034）。结论 乳腺癌患者血清NR3C2 表达水平降低，DNMT3A 表达水平升高，两者联合检测能够提高乳腺癌的诊断价值。
Abstract:
Objective To investigate the serum levels of nuclear receptor subfamily, group C, member 2 (NR3C2) and DNA(cytosine-5)-methyltransferase 3A(DNMT3A) in breast cancer patients and their clinical diagnostic value. Methods Collected 94 breast cancer patients hospitalized in Huadong Hospital Affiliated to Fudan University from May 2017 to December 2020 as breast cancer group. Another 86 healthy subjects were regarded as the control group. Serum levels of NR3C2 and DNMT3A were measured by enzyme-linked immunosorbent assay (ELISA), Pearson method was used to analyze the correlation between the expression levels of serum NR3C2 and DNMT3A in breast cancer patients, and multi-factor Logistic regression was used to analyze the influencing factors of breast cancer occurrence, and the diagnostic value of NR3C2 and DNMT3A in breast cancer was evaluated by receiver operating characteristic (ROC) curve. Results The serum NR3C2 level in the breast cancer group was 317.84±33.47 ng/L, lower than that in the control group (374.25±47.72) ng/L, and the expression level of DNMT3A was 451.63±75.47 μg/L, higher than that in the control group (349.85±63.72 μg/L)，the differences were statistically significant (t=9.243，9.729，all P<0.05). The results of Pearson analysis showed that there was a significant negative correlation between the expression level of serum NR3C2 and DNMT3A in breast cancer patients (r=-0.501，P=0.000). Logistic regression analysis showed that high level of NR3C2 was a protective factor for breast cancer (OR=0.563，95%CI：0.372 ～ 0.851， P=0.006), and high level of DNMT3A was a risk factor for breast cancer (OR=1.834，95%CI：1.249 ～ 2.693，P=0.002). ROC curve results showed that the area under the curve (AUC) of serum NR3C2 and DNMT3A in the diagnosis of breast cancer was 0.853 (0.791 ～ 0.915) and 0.930 (0.896 ～ 0.965), respectively. The AUC of the combined test was 0.969 (0.949 ～ 0.990), which was higher than that of the two tests alone (Z=3.460，1.894；P=0.000，0.034). Conclusion The expression level of serum NR3C2 in breast cancer patients is decreased, and the expression level of DNMT3A is increased. The combined detection of the two can improve the diagnostic value of breast cancer.

参考文献/References:

[1] DUMAS A, VAZ LUIS I, BOVAGNET T, et al. Impact of breast cancer treatment on employment：results of a multicenter prospective cohort study(CANTO)[J].Journal of Clinical Oncology, 2020, 38(7): 734-743.
[2] AFIFI A M, SAAD A M, AL-HUSSEINI M J, et al. Causes of death after breast cancer diagnosis: A US population-based analysis[J]. Cancer, 2020, 126(7):1559-1567.
[3] 刘晓鑫, 白春峡, 伏玉. 乳腺癌组织MAL2 和IGF-1R 蛋白表达与病理特征及预后的相关性研究[J]. 现代检验医学杂志, 2022, 37(3): 43-46, 68. LIU Xiaoxin, BAI Chunxia, FU Yu. Expression of MAL2 and IGF-1R protein in breast cancer and its correlation with pathological features and prognosis[J].Journal of Modern Laboratory Medicine, 2022, 37(3):43-46, 68.
[4] YU Miao, YU Hualong, LI Quanhui, et al. MiR-4709 overexpression facilitates cancer proliferation and invasion via downregulating NR3C2 and is an unfavorable prognosis factor in colon adenocarcinoma[J]. Journal of Biochemical and Molecular Toxicology, 2019, 33(12): e22411.
[5] GUO Jingyu, WANG Yukun, L? Bo, et al. MiR-454 performs tumor-promoting effects in oral squamous cell carcinoma via reducing NR3C2[J]. Journal of Oral Pathology & Medicine, 2020, 49(4): 286-293.
[6] MAN Xiaxia , LI Qi , WANG Baogang , et al. DNMT3A and DNMT3B in breast tumorigenesis and potential therapy [J]. Front Cell Dev Biol, 2022, 10:916725.
[7] 杨海荣, 丰树菊, 杜鹏琳. 血清DNA 甲基转移酶1、DNA 甲基转移酶3a 在宫颈癌及癌前病变中的表达及与人乳头瘤病毒感染的相关性[J]. 安徽医药,2022, 26(5): 986-990. YANG Hairong, FENG Shuju, DU Penglin. Expressions of serum DNMT1 and DNMT3A in patients with cervical cancer and precancerous lesions and their correlation with HPV infection[J]. Anhui Medical and Pharmaceutical Journal, 2022, 26(5): 986-990.
[8] 吕美玲, 马婕群, 陈海艳. 乳腺癌患者血清长链非编码RNA mir4435-2HG 表达水平与临床病理特征的相关性研究[J]. 现代检验医学杂志, 2021, 36(3): 23-26. L? Meiling, MA Jiequn, CHEN Haiyan. Correlation between expression level of serum long noncoding RNA mir4435-2HG and clinicopathological characteristics in breast cancer patients[J]. Journal of Modern Laboratory Medicine, 2021, 36(3): 23-26.
[9] SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA-A Cancer Journal for Clinicians,2021, 71(3): 209-249.
[10] FITZMAURICE C, AKINYEMIJU T F, AL LAMI F H,et al. Global, Regional, and National cancer incidence,mortality, years of life lost, years lived with disability,and disability-adjusted life-years for 29 cancer groups,1990 to 2016: a systematic analysis for the global burden of disease study[J]. JAMA Oncology, 2018,4(11): 1553-1568.
[11] CAI Rixin , TAO Xuelei , CHEN Ying , et al. Pex3 is involved in the genetic regulation of Nr3c2 expression in the amygdala of mice [J]. Psychiatry Res, 2020,285:112760.
[12] LI Jia, ZHAO Xu. NR3C2 suppresses the proliferatio n,migration,invasion and angiogenesis of colon cancer cells by inhibiting the AKT/ERK signaling pathway[J].Molecular Medicine Reports, 2022, 25(4): 133.
[13] 孙园园. NR3C2 在非小细胞肺癌中的表达调控、功能及临床意义的初步研究[D]. 长春: 吉林大学, 2022. SUN Yuanyuan. Preliminary study on the expression regulation, function and clinical significance of NR3C2 in non-small cell lung cancer[D].Changchun: Jilin University, 2022.
[14] PENG Yun, XI Xun, LI Juntao, et al. MiR-301b and NR3C2 co-regulate cells malignant properties and have the potential to be Independent prognostic factors in breast cancer[J]. Journal of Biochemical and Molecular Toxicology, 2021, 35(2): e22650.
[15] LU Jianjun, HU Fang, ZHOU Yingling. Transcriptome profile and clinical outcome in invasive breast carcinoma [J]. BioMed Research International, 2021,2021: 9025481.
[16] YU Zhaojin, XIAO Qinghuan, ZHAO Lin, et al. DNA methyltransferase 1/3a overexpression in sporadic breast cancer is associated with reduced expression of estrogen receptor-alpha/breast cancer susceptibility gene 1 and poor prognosis[J]. Molecular Carcinogenesis, 2015, 54(9): 707-719.
[17] LIU Jian, PANG Yamei, WANG Huangzhen, et al. MiR-101 inhibits the proliferation and migration of breast cancer cells via downregulating the expression of DNA methyltransferase 3a [J]. Chinese Journal of Cellular and Molecular Immunology, 2016, 32(3):299-303.
[18] IWAMOTO T, NIIKURA N, OGIYA R, et al. Distinct gene expression profiles between primary breast cancers and brain metastases from pair-matched samples[J].Scientific Reports, 2019, 9(1): 13343.

相似文献/References:

[1]党小军,张华,王欣.人附睾蛋白4(HE4)在乳腺癌诊断中的价值[J].现代检验医学杂志,2015,30(06):84.[doi:10.3969/j.issn.1671-7414.2015.06.024]
　DANG Xiao-jun,ZHANG Hua,WANG Xin.Value of Human Epididymis Protein 4(HE4) in Diagnosis of Breast Cancer[J].Journal of Modern Laboratory Medicine,2015,30(06):84.[doi:10.3969/j.issn.1671-7414.2015.06.024]
[2]张 萍,任世云,张 雷.乳腺癌患者血清脂质运载蛋白-2 和基质金属蛋白酶-9的表达及临床意义[J].现代检验医学杂志,2015,30(01):72.[doi:10.3969/j.issn.1671-7414.2015.01.019]
　ZHANG Ping,REN Shi-yun,ZHANG Lei.Expression and Clinical Significance of Serum LCN-2 and MMP-9 in Patients with Breast Cancer[J].Journal of Modern Laboratory Medicine,2015,30(06):72.[doi:10.3969/j.issn.1671-7414.2015.01.019]
[3]乔雪峰a,黄志平b,张 宁c,等.IL-18基因启动子区-137G/C,-607G/T 2个位点基因多态性与女性乳腺癌易感性Meta分析[J].现代检验医学杂志,2016,31(04):65.[doi:10.3969/j.issn.16717-414.2016.04.017]
　QIAO Xue-fenga,HUANG Zhi-pingb,ZHANG Ningc,et al.Association Analysis of IL-18 Gene Promoter Region -137G/C,-607G/T Polymorphisms and Susceptibility to Sporadic Breast Cancer:Meta-Analysis[J].Journal of Modern Laboratory Medicine,2016,31(06):65.[doi:10.3969/j.issn.16717-414.2016.04.017]
[4]刘延梅,马少君,张月浪,等.人类表皮生长因子受体2在乳腺癌表达与临床的相关病理特征分析[J].现代检验医学杂志,2016,31(05):91.[doi:10.3969/j.issn.1671-7414.2016.05.024]
　LIU Yan-mei,MA Shao-jun,ZHANG Yue-lang,et al.Expression of Human Epidermal Growth Factor Receptor 2 and Correlation with Clinical Pathological Features in Breast Cancer[J].Journal of Modern Laboratory Medicine,2016,31(06):91.[doi:10.3969/j.issn.1671-7414.2016.05.024]
[5]陈雨欣,谭婷婷,宁明哲.乳腺癌患者血清中白介素35(IL-35)的表达及其临床意义[J].现代检验医学杂志,2017,32(02):92.[doi:10.3969/j.issn.1671-7414.2017.02.025]
　CHEN Yu-xin,TAN Ting-ting,NING Ming-zhe.Serological Interleukin-35 Level in Patients with Breast Cancer and Its Clinical Significance[J].Journal of Modern Laboratory Medicine,2017,32(06):92.[doi:10.3969/j.issn.1671-7414.2017.02.025]
[6]唐努尔·艾尔肯,阿孜古·祖农.盐酸罗哌卡因对人乳腺癌细胞运动作用的研究[J].现代检验医学杂志,2017,32(03):128.[doi:10.3969/j.issn.1671-7414.2017.03.035]
　TANGNUER·Aierken,AZIGU·Zunong.Study on Effect of Ropivacaine on Migration of Breast Cancer Cell s[J].Journal of Modern Laboratory Medicine,2017,32(06):128.[doi:10.3969/j.issn.1671-7414.2017.03.035]
[7]靳庆娥,苏建荣.北京地区汉族女性人群SYK基因启动子区-803A>Trs290987单核苷酸多态性与乳腺癌易感性分析[J].现代检验医学杂志,2018,33(02):5.[doi:10.3969/j.issn.1671-7414.2018.02.001]
　JIN Qing-e,SU Jian-rong.Associations of SYK Promoter-803A >T(rs290987)Single Nucleotide Polymorphisms with Susceptibility to Breast Cancer of Han Female Population in Beijing Area[J].Journal of Modern Laboratory Medicine,2018,33(06):5.[doi:10.3969/j.issn.1671-7414.2018.02.001]
[8]高 华a,李玉柱b,韩龙才c,等.Logistic回归和ROC工作曲线评价联合检测血清CA153,TPS,CYFRA21-1在乳腺癌诊断中的临床价值[J].现代检验医学杂志,2018,33(03):60.[doi:10.3969/j.issn.1671-7414.2018.03.016]
　GAO Huaa,LI Yu-zhub,HAN Long-caic,et al.Clinical Value of Logistic Regression and ROC Work Curve Evaluating Serum CA153,TPS and Cyfra21-1 for Diagnosis of Breast Cancer[J].Journal of Modern Laboratory Medicine,2018,33(06):60.[doi:10.3969/j.issn.1671-7414.2018.03.016]
[9]李 娜a,赵晓娟b,苏晓明a.乳腺组织中SMG-1mRNA和SOX4mRNA检测在乳腺癌监测中的应用[J].现代检验医学杂志,2019,34(02):35.[doi:10.3969/j.issn.1671-7414.2019.02.010]
　LI Naa,ZHAO Xiao-juanb,SU Xiao-minga.Application of Detection of SMG-1mRNA and SOX4mRNAin Breast Tissue in Surveillance for Breast Cancer[J].Journal of Modern Laboratory Medicine,2019,34(06):35.[doi:10.3969/j.issn.1671-7414.2019.02.010]
[10]王 碧,吉茂礼.乳腺癌组织长链非编码RNA UCA1和BCAR4表达与辅助化疗效果的相关性研究[J].现代检验医学杂志,2019,34(05):77.[doi:10.3969/j.issn.1671-7414.2019.05.019]
　WANG Bi,JI Mao-li.Correlational Research on the Expressionof Long-Chain Non-Coding RNA UCA1 and BCAR4in Breast Cancer Tissues for the Effect of Adjuvant Chemotherapy[J].Journal of Modern Laboratory Medicine,2019,34(06):77.[doi:10.3969/j.issn.1671-7414.2019.05.019]

备注/Memo

备注/Memo:
作者简介：张凌捷（1981-），男，硕士，主治医师，研究方向：乳腺癌的综合治疗，E-mail：zlj0427@yeah.net。
更新日期/Last Update: 2023-11-15